Skip to content
value.today

Aspyrian Therapeutics, Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2010
Total raised
$733 M
13 rounds on record
Latest round
$9 M
Aug 2026
First round on record
Dec 2014
Today
Private
No later event on record

Funding rounds

13 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Aspyrian Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Aug 2026$9 MNo. 13$2 to $10 million

Aspyrian Therapeutics, Inc.: Raise no. 13, Aug 2026

Investors in this round

14 investors had bought by the notice of Oct 6, 2026: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhijit Bhatia · Executive Officer
  • Amy Thorne · Executive Officer
  • Anthony Manibusan · Executive Officer
  • Hassan Danesi · Executive Officer
  • Hiroyuki Kodama · Executive Officer
  • Louise Chang · Executive Officer
  • Maeda Minami · Executive Officer
  • Suzane San · Executive Officer
  • Tiffany Piecewicz · Executive Officer
  • Toshiaki Suzuki · Executive Officer
  • Christophe Weber · Director
  • David Chao · Director
  • Eiichi Kaga · Director
  • Hiroshi Mikitani · Director
  • Hiroshi Mori · Director
  • Ken Takeshita · Director
  • Mazen Darwazeh · Director
  • Miguel Garcia-Guzman · Director
  • Nitin Nohria · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D, newest notice filed Oct 6, 2026. Read the notice at the SEC.

optionsSEC
Jul 2025$112 MNo. 12$50 to $250 million

Aspyrian Therapeutics, Inc.: Raise no. 12, Jul 2025

Investors in this round

26 investors had bought by the notice of Apr 13, 2026: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$112 M of $117 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhijit Bhatia · Executive Officer
  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Hiroyuki Kodama · Executive Officer
  • Maeda Minami · Executive Officer
  • Suzane San · Executive Officer
  • Tiffany Piecewicz · Executive Officer
  • Toshiaki Suzuki · Executive Officer
  • David Chao · Director
  • Eiichi Kaga · Director
  • Hiroshi Mori · Director
  • Kentaro Hyakuno · Director
  • Mazen Darwazah · Director
  • Miguel Garcia-Guzman · Director
  • Nitin Nohria · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D, newest notice filed Apr 13, 2026. Read the notice at the SEC.

equitySEC
Dec 2024$2 MNo. 11Under $2 million

Aspyrian Therapeutics, Inc.: Raise no. 11, Dec 2024

Investors in this round

14 investors had bought by the notice of May 7, 2025: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhijit Bhatia · Executive Officer
  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Minami Maeda · Executive Officer
  • Suzane San · Executive Officer
  • Tiffany Piecewicz · Executive Officer
  • Toshiaki Suzuki · Executive Officer
  • David Chao · Director
  • Eiichi Kaga · Director
  • Hiroshi Mori · Director
  • Kentaro Hyakuno · Director
  • Mazen Darwazah · Director
  • Miguel Garcia-Guzman · Director
  • Nitin Nohria · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D and 1 amendment, newest notice filed May 7, 2025. Read the notice at the SEC.

optionsSEC
Mar 2024$4 MNo. 10$2 to $10 million

Aspyrian Therapeutics, Inc.: Raise no. 10, Mar 2024

Investors in this round

15 investors had bought by the notice of Mar 28, 2024: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhijit Bhatia · Executive Officer
  • Agatha Martindale · Executive Officer
  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Minami Maeda · Executive Officer
  • Suzane San · Executive Officer
  • Takashi Toraishi · Executive Officer, Director
  • Tiffany Piecewicz · Executive Officer
  • Toshiaki Suzuki · Executive Officer
  • David Chao · Director
  • Hiroshi Mori · Director
  • Hiroshi Takasawa · Director
  • Kentaro Hyakuno · Director
  • Mazen Darwazah · Director
  • Miguel Garcia-Guzman · Director
  • Nitin Nohria · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D, newest notice filed Mar 28, 2024. Read the notice at the SEC.

optionsSEC
Aug 2023$105 MNo. 9$50 to $250 million

Aspyrian Therapeutics, Inc.: Raise no. 9, Aug 2023

Investors in this round

15 investors had bought by the notice of Sep 1, 2023: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$105 M of $124 M offered; $19 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhijit Bhatia · Executive Officer
  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Takashi Toraishi · Executive Officer, Director
  • Tiffany Piecewicz · Executive Officer
  • David Chao · Director
  • Hiroshi Mori · Director
  • Hiroshi Takasawa · Director
  • Kentaro Hyakuno · Director
  • Mazen Darwazeh · Director
  • Miguel Garcia-Guzman · Director
  • Nitin Nohria · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Includes shares of capital stock issued pursuant to conversion of convertible notes in the amount of $73,689,146.18.”

Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D, newest notice filed Sep 1, 2023. Read the notice at the SEC.

equitySEC
Jun 2022$2 MNo. 8$2 to $10 million

Aspyrian Therapeutics, Inc.: Raise no. 8, Jun 2022

Investors in this round

20 investors had bought by the notice of Oct 4, 2023: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Abhijit Bhatia · Executive Officer
  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Takashi Toraishi · Executive Officer, Director
  • Tiffany Piecewicz · Executive Officer
  • Toshiaki Suzuki · Executive Officer
  • David Chao · Director
  • Hiroshi Mori · Director
  • Hiroshi Takasawa · Director
  • Kentaro Hyakuno · Director
  • Mazen Darwazeh · Director
  • Miguel Garcia-Guzman · Director
  • Nitin Nohria · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tiffany Piecewicz, Secretary. Source: SEC Form D and 1 amendment, newest notice filed Oct 4, 2023. Read the notice at the SEC.

optionsSEC
Jul 2021$166 MNo. 7$50 to $250 million

Aspyrian Therapeutics, Inc.: Raise no. 7, Jul 2021

Investors in this round

10 investors had bought by the notice of Jul 29, 2021: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$166 M of $291 M offered; $125 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,000,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ann McGuire · Executive Officer
  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Miguel Garcia-Guzman · Executive Officer, Director
  • Takashi Toraishi · Executive Officer, Director
  • David Chao · Director
  • Hiroshi Mori · Director
  • Hiroshi Takasawa · Director
  • Kentaro Hyakuno · Director
  • Nitin Nohria · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • TAP Securities LLC (CRD 151593) · New York, New YorkSold in AZ, CA, CO, CT, DC, FL, IL, IN, LA, MA, MD, MO, NC, NJ, NY, OR, PA, SC, TX, UT, VA, WA, and outside the US
  • Momentum Capital Markets, LLC (CRD 300288) · San Francisco, CaliforniaSold in CA, and outside the US

Signed by Brenton Keath, Chief Financial Officer and Chief Operating Officer. Source: SEC Form D, newest notice filed Jul 29, 2021. Read the notice at the SEC.

equitySEC
Dec 2020$15 MIssued in a merger or acquisition$10 to $50 million

Aspyrian Therapeutics, Inc.: Private sale, Dec 2020

Investors in this round

1 investor had bought by the notice of Jan 14, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $15 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brenton Keath · Executive Officer
  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Miguel Garcia-Guzman · Executive Officer, Director
  • Takashi Toraishi · Executive Officer, Director
  • David Chao · Director
  • Hiroshi Mori · Director
  • Kentaro Hyakuno · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Brenton Keath, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 14, 2021. Read the notice at the SEC.

equitySEC
Jul 2019$100 MNo. 6$50 to $250 million

Aspyrian Therapeutics, Inc.: Raise no. 6, Jul 2019

Investors in this round

1 investor had bought by the notice of Aug 7, 2019: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$100 M of $100 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Miguel Garcia-Guzman · Executive Officer, Director
  • Takashi Toraishi · Executive Officer, Director
  • David Chao · Director
  • Hiroshi Mori · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Takashi Toraishi, President. Source: SEC Form D, newest notice filed Aug 7, 2019. Read the notice at the SEC.

equitySEC
Aug 2018$150 MNo. 5$50 to $250 million

Aspyrian Therapeutics, Inc.: Raise no. 5, Aug 2018

Investors in this round

4 investors had bought by the notice of Nov 7, 2018: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$150 M of $350 M offered; $200 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carlos Garcia · Executive Officer
  • Hiroshi Mikitani · Executive Officer, Director
  • Merrill Biel · Executive Officer, Director
  • Miguel Garcia-Guzman · Executive Officer, Director
  • Takashi Toraishi · Executive Officer
  • Hiroshi Mori · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Hiroshi Mikitani, President. Source: SEC Form D and 2 amendments, newest notice filed Nov 7, 2018. Read the notice at the SEC.

equitySEC
Jul 2017$15 MNo. 4$10 to $50 million

Aspyrian Therapeutics, Inc.: Raise no. 4, Jul 2017

Investors in this round

45 investors had bought by the notice of Jul 21, 2017: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $19 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Merrill Biel · Executive Officer, Director
  • Miguel Garcia-Guzman · Executive Officer, Director
  • Hiroshi Mikitani · Director
  • Hiroshi Mori · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Miguel Garcia-Guzman, Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 21, 2017. Read the notice at the SEC.

equitySEC
Feb 2016$55 MNo. 3$50 to $250 million

Aspyrian Therapeutics, Inc.: Raise no. 3, Feb 2016

Investors in this round

8 investors had bought by the notice of Oct 5, 2016: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$55 M of $56 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Merrill Biel · Executive Officer, Director
  • Miguel Garcia-Guzman · Executive Officer, Director
  • Hiroshi Mikitani · Director
  • Hiroshi Mori · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Miguel Garcia-Guzman, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 5, 2016. Read the notice at the SEC.

equitySEC
Jul 2015$4 MNo. 2$2 to $10 million

Aspyrian Therapeutics, Inc.: Raise no. 2, Jul 2015

Investors in this round

3 investors had bought by the notice of Jul 30, 2015: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Merrill Biel · Executive Officer, Director
  • Miguel Garcia-Guzman · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Miguel Garcia-Guzman, President. Source: SEC Form D, newest notice filed Jul 30, 2015. Read the notice at the SEC.

equitySEC
Dec 2014$8 MNo. 1$2 to $10 million

Aspyrian Therapeutics, Inc.: Raise no. 1, Dec 2014

Investors in this round

8 investors had bought by the notice of Jan 23, 2015: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Miguel Garcia-Guzman · Executive Officer, Director
  • Scott Salka · Executive Officer, Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total amount sold includes $6,480,000 of securities issued upon conversion of the principal and interest outstanding under a convertible promissory note. Also includes $176 of Common Stock sold pursuant to a Common Stock Purchase Agreement.”

Signed by Scott Salka, Ceo. Source: SEC Form D, newest notice filed Jan 23, 2015. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Aspyrian Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2026).

    SEC Form D · Oct 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2026

That is all the official record says: Aspyrian Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Aspyrian Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 13 rounds above had up to 45 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Aspyrian Therapeutics, Inc.
NameRoleNamed in
Abhijit BhatiaExecutive officerOct 2026
Amy ThorneExecutive officerOct 2026
Anthony ManibusanExecutive officerOct 2026
Hassan DanesiExecutive officerOct 2026
Hiroyuki KodamaExecutive officerOct 2026
Louise ChangExecutive officerOct 2026
Maeda MinamiExecutive officerOct 2026
Suzane SanExecutive officerOct 2026
Tiffany PiecewiczExecutive officerOct 2026
Toshiaki SuzukiExecutive officerOct 2026
Carlos GarciaExecutive officerApr 2026
Hiroshi MikitaniExecutive officerApr 2026
Minami MaedaExecutive officerMay 2025
Agatha MartindaleExecutive officerMar 2024
Takashi ToraishiExecutive officerMar 2024
Miguel Garcia-GuzmanExecutive officerJul 2022
Ann McGuireExecutive officerJul 2021
Brenton KeathExecutive officerJan 2021
Merrill BielExecutive officerNov 2018
Scott SalkaExecutive officerJan 2015
Christophe WeberDirectorOct 2026
David ChaoDirectorOct 2026
Eiichi KagaDirectorOct 2026
Hiroshi MikitaniDirectorOct 2026
Hiroshi MoriDirectorOct 2026
Ken TakeshitaDirectorOct 2026
Mazen DarwazehDirectorOct 2026
Miguel Garcia-GuzmanDirectorOct 2026
Nitin NohriaDirectorOct 2026
Kentaro HyakunoDirectorApr 2026
Mazen DarwazahDirectorApr 2026
Hiroshi TakasawaDirectorMar 2024
Takashi ToraishiDirectorMar 2024
Merrill BielDirectorNov 2018
Scott SalkaDirectorJan 2015